Is adding fluoroquinolones to regimens for treating isoniazid-resistant tuberculosis necessary?

Roland Diel, Neil W. Schluger

Source: Eur Respir J, 54 (4) 1901494; 10.1183/13993003.01494-2019
Journal Issue: October
Disease area: Respiratory infections

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Roland Diel, Neil W. Schluger. Is adding fluoroquinolones to regimens for treating isoniazid-resistant tuberculosis necessary?. Eur Respir J, 54 (4) 1901494; 10.1183/13993003.01494-2019

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
Source: Eur Respir J 2016; 48: 582-585
Year: 2016


What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis?
Source: Eur Respir J 2009; 34: 1492-1494
Year: 2009


The efficiency of including the II-line drugs to the treatment regimen of isoniazid-resistant tuberculosis.
Source: International Congress 2017 – MDRTB: detection and management
Year: 2017

Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
Source: Eur Respir J 2008; 31: 1155-1159
Year: 2008



Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India
Source: Eur Respir J 2012; 39: 956-962
Year: 2012



The individual-tailored treatment regimens for multidrug-resistant tuberculosis
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012


A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 722s
Year: 2004

Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis
Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017
Year: 2017



Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis
Source: Eur Respir J 2013; 42: 504-512
Year: 2013



The efficacy of a rifabutin-containing regimen for rifabutin-susceptible multidrug-resistant tuberculosis
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012


Recommending prolonged bedaquiline use for the treatment of highly resistant strains of tuberculosis
Source: Eur Respir J, 50 (5) 1701552; 10.1183/13993003.01552-2017
Year: 2017



Treatment of resistant tuberculosis in patients having isolates resistant to multiple antituberculosis drugs
Source: Annual Congress 2010 - Prognosis of tuberculosis
Year: 2010

Administration of linezolid, bedaquiline and imipenem in treatment of patients with extensively drug-resistant tuberculosis
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015

Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM)
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011

Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis
Source: Eur Respir J, 57 (4) 2004454; 10.1183/13993003.04454-2020
Year: 2021



Treatment of TB
Source: Eur Respir Mon 2012; 58: 154-166
Year: 2012


Safety and efficacy of linezolid, clarithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis
Source: Eur Respir J 2006; 28: Suppl. 50, 587s
Year: 2006

The efficacy of treatment of patients with drug resistant tuberculosis
Source: Eur Respir J 2007; 30: Suppl. 51, 661s
Year: 2007

A study of role of rifabutin as an adjuvant in management of cases with multi-drug resistant pulmonary tuberculosis
Source: Annual Congress 2007 - Medical and surgical treatment of susceptible and resistant tuberculosis
Year: 2007


A UK cost comparison of amikacin therapy with bedaquiline, for drug resistant tuberculosis
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020